A cheap and widely used steroid called dexamethasone has become the first drug shown to be able to save lives among COVID-19 patients in what scientists said is a “major breakthrough” in the coronavirus pandemic.

Children have milder COVID-19 symptoms than adults and the balance of evidence suggests they may also have lower susceptibility and infectivity than adults, scientists advising the British government said.

Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.

Healthcare workers in Britain and Thailand started taking part in a trial to determine whether two anti-malarial drugs can prevent COVID-19, including one that U.S. President Donald Trump says he has been taking.

Britain is in talks with Swiss drugmaker Roche Holding AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.

British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?

The United Kingdom’s COVID-19 death toll exceeds 40,000, by far the worst yet reported in Europe, raising more questions about Prime Minister Boris Johnson’s handling of the coronavirus crisis.

Pregnant women are no more likely to become severely ill with COVID-19 than other women, according to a preliminary study in Britain, but most expectant mothers who do develop serious illness tend to be in the later stages of pregnancy.

Britain will trial a new coronavirus tracing program on the Isle of Wight, just off the south coast of England, cabinet minister Michael Gove said on Sunday as the government looks at how to minimise the risk of a second wave of infection.

Cobra Biologics, a manufacturer of a possible COVID-19 vaccine being developed by British scientists, may know by the end of May if the firm can make a million doses a month with a view to building stocks for commercial supply when the vaccine is approved.